Buchanan, Robert W.

The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009

Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., & Dixon, L. B. (2010) · Schizophrenia Bulletin

Schizophrenia research and treatmentClinical practice guidelines implementation

Cited by 499

A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia

Buchanan, R. W. (2005) · Schizophrenia Bulletin

Schizophrenia research and treatmentStatistical Methods in Clinical Trials

Cited by 438

Initial phase 2 trial of a nicotinic agonist in schizophrenia

Freedman, R., Olincy, A., Buchanan, R. W., Harris, J. G., Gold, J. M., Johnson, L., Allensworth, D., Guzman-Bonilla, A., Clement, B., Ball, M. P., et al. (2008) · American Journal of Psychiatry

Nicotinic Acetylcholine Receptors StudySchizophrenia research and treatment

Cited by 426

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

Buchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry

Schizophrenia research and treatmentAmino Acid Enzymes and Metabolism

Cited by 419

Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine

Hong, L. E., Summerfelt, A., Buchanan, R. W., O'Donnell, P., Thaker, G. K., Weiler, M. A., & Lahti, A. C. (2010) · Neuropsychopharmacology

Schizophrenia research and treatmentNeural dynamics and brain function

Cited by 274

Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia

Marx, C. E., Keefe, R. S. E., Buchanan, R. W., Hamer, R. M., Kilts, J. D., Bradford, D. W., Strauss, J. L., Naylor, J. C., Payne, V. M., Lieberman, J. A., et al. (2009) · Neuropsychopharmacology

Schizophrenia research and treatmentTreatment of Major Depression

Cited by 193

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia

Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 172

Galantamine for the treatment of cognitive impairments in people with schizophrenia

Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., & McMahon, R. P. (2008) · American Journal of Psychiatry

Schizophrenia research and treatmentDementia and Cognitive Impairment Research

Cited by 170

The FDA-NIMH-MATRICS Guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Buchanan, R. W., Keefe, R. S. E., Umbricht, D., Green, M. F., Laughren, T., & Marder, S. R. (2011) · Schizophrenia Bulletin

Schizophrenia research and treatmentStatistical Methods in Clinical Trials

Cited by 154

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe, R. S. E., Buchanan, R. W., Marder, S. R., Schooler, N. R., Dugar, A., Zivkov, M., & Stewart, M. (2013) · Schizophrenia Bulletin

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 138

Sensory gating endophenotype based on its neural oscillatory pattern and heritability estimate

Hong, L. E., Summerfelt, A., Mitchell, B. D., McMahon, R. P., Wonodi, I., Buchanan, R. W., & Thaker, G. K. (2008) · Archives of General Psychiatry

Schizophrenia research and treatmentNeural dynamics and brain function

Cited by 115

Morphometric Assessment of the Heteromodal Association Cortex in Schizophrenia

Buchanan, R. W., Francis, A., Arango, C., Miller, K., Lefkowitz, D. M., McMahon, R. P., Barta, P. E., & Pearlson, G. D. (2004) · American Journal of Psychiatry

Schizophrenia research and treatmentMental Health and Psychiatry

Cited by 97

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: Results from a randomized double blind placebo controlled pilot study

Lee, M. R., Wehring, H. J., McMahon, R. P., Linthicum, J., Cascella, N., Liu, F., Bellack, A., Buchanan, R. W., Strauss, G. P., Contoreggi, C., et al. (2013) · Schizophrenia Research

Schizophrenia research and treatmentOlfactory and Sensory Function Studies

Cited by 80

Smooth pursuit eye movements to extra-retinal motion signals: deficits in patients with schizophrenia

Thaker, G. K., Ross, D. E., Buchanan, R. W., Adami, H. M., & Medoff, D. R. (1999) · Psychiatry Research

Schizophrenia research and treatmentMotor Control and Adaptation

Cited by 71

A resting state fMRI analysis pipeline for pooling inference across diverse cohorts: an ENIGMA rs-fMRI protocol

Adhikari, B. M., Jahanshad, N., Shukla, D., Turner, J., Grotegerd, D., Dannlowski, U., Kugel, H., Engelen, J., Dietsche, B., Krug, A., et al. (2019) · Brain Imaging and Behavior

Functional Brain Connectivity StudiesAdvanced MRI Techniques and Applications

Cited by 53

Evidence of reward system dysfunction in youth at clinical high-risk for psychosis from two event-related fMRI paradigms

Millman, Z. B., Gallagher, K., Demro, C., Schiffman, J., Reeves, G. M., Gold, J. M., Rakhshan Rouhakhtar, P. J., Fitzgerald, J., Andorko, N. D., Redman, S., et al. (2020) · Schizophrenia Research

Schizophrenia research and treatmentNeural and Behavioral Psychology Studies

Cited by 39

Advancing drug discovery for schizophrenia

Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., Welnberger, D. R., Karayiorgou, M., Guidotti, A., Gingrich, J., et al. (2011) · Annals of the New York Academy of Sciences

Schizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Cited by 25